The FDA has expanded the indication for Menactra (meningococcal [Groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine; Sanofi Pasteur) to include a two-dose schedule for infants and children 9–23 months old. This approval was based on results from one Phase 2 and three Phase 3 trials on more than 3,300 infants showing that two doses of Menactra given 3 months apart elicits a robust immune response against the serogroups included in the vaccine. The studies also showed that the measles-mumps-rubella-varicella vaccine (MMRV) and pneumococcal conjugate vaccine (PCV7) can be administered concomitantly with Menactra in children.

Menactra is already indicated for meningitis immunization in patients 2–55 years old.

For more information call (800) VACCINE or visit